The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer.
J. Liu
Research Funding - AstraZeneca
G. F. Fleming
No relevant relationships to disclose
S. M. Tolaney
No relevant relationships to disclose
M. J. Birrer
No relevant relationships to disclose
R. T. Penson
Research Funding - AstraZeneca
S. T. Berlin
Research Funding - AstraZeneca
C. Whalen
Research Funding - AstraZeneca
K. Tyburski
Research Funding - AstraZeneca
K. Matijevich
No relevant relationships to disclose
E. Kasparian
No relevant relationships to disclose
M. Roche
No relevant relationships to disclose
H. Lee
No relevant relationships to disclose
E. P. Winer
No relevant relationships to disclose
S. P. Ivy
No relevant relationships to disclose
U. Matulonis
Research Funding - AstraZeneca